Immunoconjugates of antibodies with toxic agents are becoming a significant component
of anticancer treatments. One ongoing challenge to the success of this approach is
the exposure of healthy tissues to the cytotoxic agents employed. We propose that
magnetic fluid hyperthermia, using pre-targeted antibody-iron oxide magnetic nanoparticles,
can address this issue. In magnetic fluid hyperthermia an alternating magnetic field
is applied to magnetic nanoparticles in target tissues causing localised heating and
cell death. The externally employed magnetic field can be focused on the tumour deposit.
The system has potential to provide potent and selective cancer-targeted hyperthermic
therapy.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Plastic, Reconstructive & Aesthetic SurgeryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
O24
Identification
Copyright
© 2007 Published by Elsevier Inc.
